These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 36361723)
1. Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer. Jang H; Choi CM; Lee SH; Lee S; Jeong MK Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361723 [TBL] [Abstract][Full Text] [Related]
2. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Jamal-Hanjani M; Wilson GA; Horswell S; Mitter R; Sakarya O; Constantin T; Salari R; Kirkizlar E; Sigurjonsson S; Pelham R; Kareht S; Zimmermann B; Swanton C Ann Oncol; 2016 May; 27(5):862-7. PubMed ID: 26823523 [TBL] [Abstract][Full Text] [Related]
3. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970 [No Abstract] [Full Text] [Related]
4. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856 [TBL] [Abstract][Full Text] [Related]
5. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis. Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446 [TBL] [Abstract][Full Text] [Related]
6. Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible. Jensen TJ; Goodman AM; Ellison CK; Holden KA; Kato S; Kim L; Daniels GA; Fitzgerald K; McCarthy E; Nakashe P; Mazloom AR; Almasri E; McLennan G; Grosu DS; Eisenberg M; Kurzrock R Mol Cancer Ther; 2021 Nov; 20(11):2274-2279. PubMed ID: 34465593 [TBL] [Abstract][Full Text] [Related]
7. Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation. Anderson CJ; Yang H; Parsons J; Ahrens WA; Jagosky MH; Hsu JH; Patt JC; Kneisl JS; Steuerwald NM Clin Orthop Relat Res; 2024 Jun; 483(1):39-48. PubMed ID: 38905450 [TBL] [Abstract][Full Text] [Related]
8. Copy number alterations detected by whole-exome and whole-genome sequencing of esophageal adenocarcinoma. Wang X; Li X; Cheng Y; Sun X; Sun X; Self S; Kooperberg C; Dai JY Hum Genomics; 2015 Sep; 9(1):22. PubMed ID: 26374103 [TBL] [Abstract][Full Text] [Related]
9. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing. Yu Y; Qian J; Shen L; Ji W; Lu S Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109 [TBL] [Abstract][Full Text] [Related]
10. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing. Ge G; Peng D; Guan B; Zhou Y; Gong Y; Shi Y; Hao X; Xu Z; Qi J; Lu H; Zhang X; Zhan Y; Li Y; Wu Y; Ding G; Shen Q; He Q; Li X; Zhou L; Ci W Clin Chem; 2020 Jan; 66(1):188-198. PubMed ID: 31811000 [TBL] [Abstract][Full Text] [Related]
11. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer. Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176 [TBL] [Abstract][Full Text] [Related]
12. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279 [TBL] [Abstract][Full Text] [Related]
13. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953 [No Abstract] [Full Text] [Related]
14. Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients. Dietz S; Schirmer U; Mercé C; von Bubnoff N; Dahl E; Meister M; Muley T; Thomas M; Sültmann H PLoS One; 2016; 11(8):e0161012. PubMed ID: 27529345 [TBL] [Abstract][Full Text] [Related]
15. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC. Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431 [TBL] [Abstract][Full Text] [Related]
16. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130 [TBL] [Abstract][Full Text] [Related]
17. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients. Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127 [TBL] [Abstract][Full Text] [Related]
18. Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data. Oh S; Geistlinger L; Ramos M; Morgan M; Waldron L; Riester M JCO Clin Cancer Inform; 2020 Apr; 4():321-335. PubMed ID: 32282230 [TBL] [Abstract][Full Text] [Related]
19. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773 [TBL] [Abstract][Full Text] [Related]
20. PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach. Beagan JJ; Drees EEE; Stathi P; Eijk PP; Meulenbroeks L; Kessler F; Middeldorp JM; Pegtel DM; Zijlstra JM; Sie D; Heideman DAM; Thunnissen E; Smit L; de Jong D; Mouliere F; Ylstra B; Roemer MGM; van Dijk E J Mol Diagn; 2021 Nov; 23(11):1553-1563. PubMed ID: 34454114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]